20:16 , Mar 24, 2017 |  BC Week In Review  |  Company News

Critical Path biomarker consortium

The Critical Path Institute launched a consortium that will aim to qualify biomarkers for Type I diabetes with FDA and EMA. The Leona M. and Harry B. Helmsley Charitable Trust, the Janssen Research & Development...
21:59 , Mar 21, 2017 |  BC Extra  |  Politics & Policy

C-PATH consortium seeks to qualify diabetes biomarkers

The Critical Path Institute (Tucson, Ariz.) launched a consortium that will aim to qualify biomarkers for Type I diabetes with FDA and EMA. The Leona M. and Harry B. Helmsley Charitable Trust , the Janssen...
23:52 , Feb 24, 2017 |  BC Extra  |  Clinical News

A T-cell gene signature in infants could predict Type I diabetes

German researchers published a gene signature found in T cells from six month old infants that preceded the development of β cell autoantibodies in those at high risk for Type I diabetes. The paper was...
07:00 , Oct 6, 2014 |  BioCentury  |  Emerging Company Profile

Nirmidas: Improving NIR-sightedness

Nirmidas Biotech Inc. 's pGOLD platform can amplify the signal output of near-infrared fluorescent dyes over a hundredfold, which improves their sensitivity for low-concentration analytes in ELISA or other assays that rely on fluorescent readouts....
07:00 , Oct 27, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Pain Histone deacetylase (HDAC); glutamate decarboxylase 2 (GAD2; GAD65) Rodent studies suggest inhibiting HDACs could help treat chronic pain. In a rat model of irritant-induced...
01:18 , Jun 24, 2011 |  BC Extra  |  Clinical News

Diamyd falls after second Phase III miss

Diamyd Medical AB (SSE:DIAM B) fell SEK1.60 (15%) to SEK9 on Thursday after the company said it will discontinue the U.S. Phase III DiaPrevent trial of subcutaneous Diamyd to treat newly diagnosed Type I diabetics....
07:00 , Jun 6, 2011 |  BC Week In Review  |  Company News

Diamyd, J&J deal

Johnson & Johnson's Ortho-McNeil-Janssen Pharmaceuticals Inc. subsidiary terminated a 2010 deal with Diamyd and returned rights to diabetes candidate Diamyd. In May, the product missed the primary endpoint in a European Phase III trial to...
00:08 , Jun 2, 2011 |  BC Extra  |  Top Story

J&J returns Diamyd rights

Johnson & Johnson (NYSE:JNJ) subsidiary Ortho-McNeil-Janssen Pharmaceuticals Inc. terminated a 2010 deal with Diamyd Medical AB (SSE:DIAM B) and returned rights to diabetes candidate Diamyd. The news sent shares of Diamyd falling SEK1.40 (12%) to...
07:00 , Jun 28, 2010 |  BC Week In Review  |  Company News

Diamyd Medical, J&J deal

Diamyd granted Johnson & Johnson's Ortho-McNeil-Janssen Pharmaceuticals Inc. unit exclusive rights to Diamyd diabetes vaccine outside Nordic countries. The recombinant human glutamic acid decarboxylase (GAD65) subcutaneous vaccine is in two Phase III trials to treat...
07:00 , Jun 28, 2010 |  BioCentury  |  Finance

Regulatory Milestones

Regulatory milestones Celgene Corp. (NASDAQ:CELG) gained $0.72 to $56.07 last week after Japan's Ministry of Health, Labor and Welfare (MHLW) approved Revlimid lenalidomide in combination with dexamethasone to treat relapsed or refractory multiple myeloma (MM)....